Health Canada stalls Osiris's Prochymal stem cell therapy for GvHD
This article was originally published in Scrip
Executive Summary
Osiris Therapeutics, based in Columbia, Maryland, said that Canadian regulators requested additional information to support the company's request to approve its stem cell therapy Prochymal for the treatment of graft-v-host disease (GvHD). Canada has been the first regulatory submission for the therapy.